Cordis hopes to win back share of the stent market with the launch of a new raft of products
This article was originally published in Clinica
Executive Summary
Johnson & Johnson investors have been waiting more than a year for its Cordis interventional cardiology business to launch new stent products. In late 1997, Cordis lost its position as the supplier of the world's favourite coronary stent as competing products began hitting the market. Now, despite the launch of a balloon-expandable version of the device in 1998, sales of the Palmaz-Schatz stent have been lost almost entirely to Guidant, Boston Scientific and Medtronic (AVE). Since then, all has been relatively quiet on the stent front at Cordis.
You may also be interested in...
Fujifilm Demonstrates Health Specialism With European HealthTech Spinout
From X-ray film in 1936 to the world’s first digital X-ray system in 1983, Fujifilm has a long heritage in medical diagnostics.
Financing Quarterly Statistics, Q1 2024
During Q1, biopharmas brought in an aggregate $30.1bn in financing and device company fundraising totaled $2.8bn; while in vitro diagnostic firms and research tools players raised $724m.
Helping Organizations Deliver On KPIs And Giving Staff A Voice
ImproveWell has won awards for its software technology that allows health care staff at the sharp end of patient care to report on problems as they happen. The outcome is a real-time learning process that contributes to improved operational efficiencies for health systems, says In Vivo Rising Leader Lara Mott.